Vaxart, Inc. (VXRT) stock
Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –
Vaxart, Inc. grew revenue 22.3% to $181.27M over the twelve months to Sep 30, 2026. Free cash flow was $31.97M. At the latest close the market valued the company at $115.61M, 4.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $115.61M
- P/E ratio
- 4.0
- Price to sales
- 0.64
- Price to book
- 1.74
- Dividend yield
- –
- Free cash flow yield
- 27.65%
Fundamentals
- Revenue
- $181.27M
- Net income
- $29.04M
- EPS, diluted
- $0.12
- Free cash flow
- $31.97M
- Book value per share
- $0.27
- Diluted shares
- 243M
Trading
- Next earnings
- Mar 11, 2027 (estimated, during market hours)
- Previous close
- $0.45
- Open
- $0.45
- Day's range
- $0.45 – $0.53
- Volume
- 793,185
- Average volume (20 days)
- 294,909
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | VXRT | S&P 500 | Difference | VXRT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.2% | +0.6% | −2.8 pts | ||
| 3 months | -7.7% | +3.4% | −11.0 pts | ||
| Year to date | +37.3% | +13.3% | +24.0 pts | ||
| 1 year | +32.1% | +16.6% | +15.5 pts | ||
| 3 years | -32.1% | +86.4% | −118.4 pts | -12.1% | +23.1% |
| 5 years | -93.3% | +81.9% | −175.1 pts | -41.7% | +12.7% |
| 10 years | -97.1% | +318.9% | −416.0 pts | -29.9% | +15.4% |
Fifteen years at a glance
Fiscal years 2008 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vaxart filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- News
- Update
About Vaxart
Biological Products, (No Diagnostic Substances)
Vaxart, Inc. is a clinical-stage biotechnology company that develops oral recombinant vaccines in tablet form using its proprietary Vector-Adjuvant-Antigen Standardized Technology platform. Its product pipeline includes prophylactic vaccine candidates designed to protect against infectious diseases such as norovirus, coronavirus, and seasonal and avian influenza. Additionally, the company is advancing preclinical therapeutic vaccine candidates targeting human papillomavirus-related cervical cancer and dysplasia. Vaxart designs its enteric-coated tablet candidates for broad populations, including adults, children, and infants via passive maternal transfer, and partners with organizations like the Bill & Melinda Gates Foundation and governmental agencies such as BARDA.
Company profile, executives and historyVaxart stock: common questions
What is Vaxart's stock price?
VXRT closed at $0.48 on Oct 19, 2026, up 5.04% on the day.
What is Vaxart's market cap?
Vaxart was worth $115.61M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is VXRT's P/E ratio?
VXRT trades at 4.0 times earnings, based on diluted earnings per share of $0.12 over the twelve months to Sep 30, 2026.
How much revenue does Vaxart make?
Vaxart reported revenue of $181.27M for the twelve months to Sep 30, 2026, up 22.3% from a year earlier.
Does Vaxart pay a dividend?
No. Vaxart has not paid a cash dividend over the last twelve months.
When does Vaxart report earnings next?
Vaxart is expected to report Q4 FY2026 results on Mar 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has VXRT stock performed over the past year?
Including dividends, VXRT returned +32.1% over the past year, against +16.6% for the S&P 500.
Who are Vaxart's competitors?
Companies most similar to Vaxart by business, industry and size include VIR, VALN, NVAX, ALEC, FDMT.
See a number that looks wrong?